Use of high-throughput mass spectrometry to reduce false positives in protease uHTS screens

Journal of Biomolecular Screening

Volumn 20, Issue 2, 2015, Pages 212-222

  Adam, Gregory C ^a   Meng, Juncai ^a   Rizzo, Joseph M ^a   Amoss, Adam ^a   Lusen, Jeffrey W ^a   Patel, Amita ^a   Riley, Daniel ^a   Hunt, Rachel ^a   Zuck, Paul ^a   Johnson, Eric N ^a,b   Uebele, Victor N ^a   Hermes, Jeffrey D ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Wuxi Apptech   (United States)

Author keywords

false positives; high throughput mass spectrometry; protease; RapidFire; uHTS

Indexed keywords

ASPARTIC PROTEINASE; CYSTEINE; FLUORESCENT DYE; PROTEINASE; SERINE; PEPTIDE HYDROLASE; PROTEINASE INHIBITOR;

ARTICLE; CONTROLLED STUDY; ENZYME ASSAY; FALSE POSITIVE RESULT; FLUORESCENCE; HIGH THROUGHPUT MASS SPECTROMETRY ASSAY; HIGH THROUGHPUT SCREENING; LUMINESCENCE; MASS SPECTROMETRY; PRIORITY JOURNAL; DOSE RESPONSE; DRUG DEVELOPMENT; ENZYME SPECIFICITY; HUMAN; METABOLISM; PROCEDURES; REPRODUCIBILITY; STANDARDS;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; ENZYME ASSAYS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MASS SPECTROMETRY; PEPTIDE HYDROLASES; PROTEASE INHIBITORS; REPRODUCIBILITY OF RESULTS; SUBSTRATE SPECIFICITY;

EID: 84921455081     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057114555832     Document Type: Article

References (35)

1. Puente X., Sanchez L., Lopez-Otin C. O. C. Human and Mouse Proteases: A Comparative Genomic Approach. Nat. Rev. Genet. 2003 ; 4: 544-558
2. Turk B. Targeting Proteases: Successes, Failures and Future Prospects. Nat. Rev. Drug Discov. 2006 ; 5: 785-799
3. Marks K., Jacobsen I. The First Wave: HCV NS3 Protese Inhibitors Telaprevir and Boceprevir. Antivir. Ther. 2012 ; 17: 1119-1131
4. Sureshkumar K. Renin Inhibition with Aliskiren in Hypertension: Focus on Aliskiren/Hydrochlorothiazide Combination Therapy. Vasc. Health Risk Manag. 2008 ; 4: 1205-1220
5. Thornberry N., Weber A. Discovery of Januvia (Sitagliptin), a Selective Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes. Curr. Top Med. Chem. 2007 ; 7: 557-568
6. Drag M., Salvesen G. Emerging Principles in Protease-Based Drug Discovery. Nat. Rev. Drug Discov. 2010 ; 9: 600-701
7. Thorne N., Auld D., Inglese J. Apparent Activity in High-Throughput Screening: Origins of Compound-Dependent Assay Interference. Curr. Opin. Chem. Biol. 2010 ; 14 (3). 315-324
8. Heise C., Murray J., Augustyn K. E., et al. Mechanistic and Structural Understanding of Uncompetitive Inhibitors of Caspase-6. PLOS One. 2012 ; 7 (12). e50864
9. Beher D., Wu J., Cumine S., et al. Resveratrol Is Not a Direct Activator of SIRT1 Enzyme Activity. Chem. Biol. Drug Des. 2009 ; 74: 619-624
10. Dai H., Kustigian L., Carney D., et al. SIRT1 Activation by Small Molecules Kinetic and Biophysical Evidence for Direct Interaction of Enzyme and Activator. J. Biol. Chem. 2010 ; 285 (43). 32695-32703
11. Pacholec M., Bleasdale J., Chrunyk B., et al. SRT1720, SRT2183, SRT1460, and Resveratrol Are Not Direct Activators of SIRT1. J. Biol. Chem. 2010 ; 285 (11). 8340-8351
12. Jonas M., LaMarr W., Ozbal C. Mass Spectrometry in High-Throughput Screening: A Case Study on Acetyl-Coenzyme A Carboxylase Using RapidFire Mass Spectrometry (RF-MS). Comb. Chem. High Throughput Screen. 2009 ; 12 (8). 752-759
13. Atkinson K., Beretta E., Brown J., et al. N-Benzylimidazole Carboxamides as Potent, Orally Active StearoylCoA Desaturase-1 Inhibitors. Bioorg. Med. Chem. Lett. 2011 ; 21 (6). 1621-1625
14. Highkin M., Yates M., Nemirovskiv O., et al. High-Throughput Screening Assay for Sphingosine Kinase Inhibitors in Whole Blood Using RapidFire Mass Spectrometry. J. Biomol. Screen. 2011 ; 16 (2). 272-277
15. Holt T., Choi B., Geghagen N., et al. Label-Free High-Throughput Screening via Mass Spectrometry: A Single Cystathionine Quantitative Method for Multiple Applications. Assay Drug Dev. Technol. 2009 ; 7 (5). 495-506
16. Hutchinson S., Leveridge M., Heathcote M., et al. Enabling Lead Discovery for Histone Lysine Demethylases by High-Throughput RapidFire Mass Spectrometry. J. Biomol. Screen. 2012 ; 17 (1). 39-48
17. Langsdorf E., Malikzav A., LaMarr W., et al. Screening of Antibacterial Inhibitors of the UDP-3-O-(R-3-Hydroxymyristoyl)-N-Acetylglucosamine Deacetlase (LpxC) Using a High-Throughput Mass Spectrometry Assay. J. Biomol. Screen. 2010 ; 15 (1). 52-61
18. Leveridge M., Buxton R., Argryou A., et al. Demonstrating Enhanced Throughput of RapidFire Mass Spectrometry through Multiplexing Using the JmjD2d Demethylase as a Model System. J. Biomol. Screen. 2014 ; 19 (2). 278-286
19. Plant M., Dineen T., Cheng A., et al. Screening for Lysine-Specific Demethylase-1 Inhibitors Using a Label-Free High-Throughput Mass Spectrometry Assay. Anal. Biochem. 2011 ; 419 (2). 217-227
20. Quercia A., LaMarr W., Myung J., et al. High-Throughput Screening by Mass Spectrometry: Comparison with the Scintillation Proximity Assay with a Focused-File Screen of AKT1/PKB Alpha. J. Biomol. Screen. 2007 ; 12 (4). 473-480
21. Soulard P., McLaughlin M., Stevens J., et al. Development of a High-Throughput Screening Assay for Stearoyl-CoA Desaturase Using Rat Liver Microsomes, Deuterium Labeled Stearoyl-CoA and Mass Spectrometry. Anal. Chim. Acta. 2008 ; 627: 105-111
22. O'Brien P., Mureebe L. Direct Thrombin Inhibitors. J. Cardiovasc. Pharmacol. Ther. 2012 ; 17 (1). 5-11
23. Warby S. C., Doty C. N., Graham R. K., et al. Activated Caspase-6 and Caspase-6 Cleaved Fragments of Huntingtin Specifically Colocalize in the Nucleus. Hum. Mol. Gen. 2008 ; 17 (15). 2390-2404
24. Horowitz P. M., Patterson K. R., Guillozet-Bougaarts A. L., et al. Early N-Terminal Changes and Caspase-6 Cleavage of Tau in Alzheimer's Disease. J. Neurosci. 2004 ; 24 (36). 7895-7902
25. Graham R., Ehrnhoefer D., Hayden M. Caspase-6 and Neurodegeneration. Trends Neurosci. 2011 ; 34 (12). 646-656
26. Vassay R., Kovacs D., Yan R., et al. The β-Secretase Enzyme BACE in Health and Alzheimer's Disease: Regulation, Cell Biology, Function, and Therapeutic Potential. J. Neurosci. 2009 ; 29 (41). 12787-12794
27. Gulnik S., Erickson J., Xie D. HIV Protease: Enzyme Function and Drug Resistance. Vitam. Horm. 2000 ; 58: 213-256
28. Sardana V., Xu B., Zugay-Murphy J., et al. A General Procedure for the Purification of Human β-Secretase Expressed. Escherichia coli. Protein Expr. Purif. 2004 ; 34: 190-196
29. Aoyama T., Ino Y., Ozeki M., et al. Pharmacological Studies of FUT-175, Nafamstat mesilate. I. Inhibiton of Protease Activity in In Vitro and In Vivo Experiments. Jpn. J. Pharmacol. 1984 ; 35 (3). 203-227
30. Trumbo T., Maurer M. Examining Thrombin Hydrolysis of the Factor XIII Activation Peptide Segment Leads to a Proposal for Explaining the Cardioprotective Effects Observed with the Factor XIII V34L Mutation. J. Biol. Chem. 2000 ; 27 (7). 20627-20631
31. Kennedy M., Wang W., Song L., et al. Measuring Human β-Secretase (BACE1) Activity Using Homogeneous Time-Resolved Fluorescence. Anal. Biochem. 2003 ; 319: 49-55
32. Zhang J.-H., Chung T., Oldenburg K. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J. Biomol. Screen. 1999 ; 4: 67-73
33. Brideau C., Gunter B., Pikounis B., et al. Improved Statistical Methods for Hit Selection in High-Throughput Screening. J. Biomol. Screen. 2003 ; 8: 634-647
34. Stennicke H. R., Renatus M., Meldal M., et al. Internally Quenched Fluorescent Peptide Substrates Disclose the Subsite Preferences of Human Caspases 1,3,6,7 and 8. Biochem. J. 2000 ; 350: 563-568
35. Schoichet B. Screening in a Spirit Haunted World. Drug Discov. Today. 2006 ; 11 (13-14). 607-615